WATCH: A paradigm shift in the management of TED

Andrew Lee, MD, and Elizabeth Fortin, MD, discuss a paradigm shift in the treatment of thyroid eye disease with the new FDA approved medicine for managing TED.

In this week's discussion, Andrew Lee, MD, and Elizabeth Fortin, MD, disucss Teprotumumab, the first and only FDA approved medicine to treat thyroid eye disease (TED). They talk about the impact the drug can have on patients, cost considerations and how to use the treatment in the clinic.

Related Content:

VideosBlogsClinicalTherapeutics
Higher rates of repeat corneal crosslinking need found in younger patients
Robot-assisted micro interventional glaucoma surgery reduces surgeon's tremors
Choosing among DSAEK, DMEK and DSO for endothelial keratoplasty